

UNITED STATES
NUCLEAR REGULATORY COMMISSION

+ + + + +

MEETING WITH ADVISORY COMMITTEE ON
REACTOR SAFEGUARDS

+ + + + +

FRIDAY,
JUNE 9, 2023

+ + + + +

The Commission met in the Commissioners' Hearing Room,
at 10:00 a.m., Christopher T. Hanson, Chair, presiding.

COMMISSION MEMBERS:

- CHRISTOPHER T. HANSON, Chair
- JEFF BARAN, Commissioner
- DAVID A. WRIGHT, Commissioner
- ANNIE CAPUTO, Commissioner
- BRADLEY R. CROWELL, Commissioner

ALSO PRESENT:

- BROOKE P. CLARK, Secretary of the Commission
- MARIAN ZOBLER, General Counsel

ACRS MEMBERS PRESENT:

JOY REMPE, Chairman, Advisory Committee on Reactor

Safeguards (ACRS)

RON BALLINGER, Member, ACRS

VICKI BIER, Member, ACRS

WALT KIRCHNER, Vice Chair, ACRS

DAVID PETTI, Member-at-Large, ACRS

P R O C E E D I N G S

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

10:00 a.m.

CHAIR HANSON: Good morning, everyone, and happy Friday. I convene the Nuclear Regulatory Commission's public meeting for the purposes of hearing from members of the NRC's independent Advisory Committee on Reactor Safeguards, or ACRS, on issues recently reviewed by the Committee.

Welcome, everyone. And welcome to Commissioner Caputo, too. She's online with us, and will be joining us via Teams this morning, and look forward to her questions.

The ACRS plays an important role in the statutory structure of the NRC. It's intended to be a built-in review body with significant discretion and independence. This independence is even more important for new reactor reviews that will include significant novel considerations and issues associated with new technologies. Feedback from the ACRS is going to be critical.

That's why I'm glad to see the addition of Dr. Martin. Welcome, Dr. Martin. He brings significant experience over 30 years in nuclear reactor safety, and most recently as a technical consultant, I believe, for BWX Technologies. You have significant experience in accident analysis methodologies and code development support, and we look forward to your contributions. Thank you.

I also want to acknowledge up-front the Committee's good work recently, and value-add in the recent review of fusion regulatory options, and also identifying issues such as the density wave oscillation and the boron

1 redistribution issues with the NuScale design. So, thank you for that. We're
2 going to be hearing from our ACRS panelists on a number of interesting topics
3 to include both NuScale and Kairos and others, and Part 53's.

4 But before we get rolling with those presentations, I'll ask my
5 colleagues if they have any remarks they'd like to make.

6 (Pause.)

7 CHAIR HANSON: Okay, with that, Dr. Rempe, I'll hand it over
8 to you.

9 DR. REMPE: Thank you, Chair Hanson, and good morning,
10 Chair Hanson and the Commissioners. The ACRS does appreciate the
11 opportunity to meet with you. Slide two shows the agenda for this briefing.
12 There'll be five presentations, after my overview we'll hear from Member
13 Ballinger about the SHINE medical isotopes operating license application,
14 followed by Member Kirchner on the NuScale topical report for the emergency
15 planning zone site boundary associated with the plume exposure pathway. And
16 finally, Member Petti will provide an overview of our reports on the Part 53
17 rulemaking, and the Kairos Hermes construction permit application.

18 Since our last briefing with you, which was in June, 2022,
19 we've issued 17 letter reports. Four of these reports pertaining to fusion energy
20 system regulation in the Part 53 rulemaking package. Slide four lists the letter
21 reports we've issued pertaining to submittals for design centered application.

22 Our review of the SHINE, and the Kairos applications applied
23 an approach that we first applied in the phase four NuScale ECA application, as
24 you may recall. The staff of the ACRS along with NRR staff worked together to

1 implement this evolving report. The lead member will assign members with
2 relevant expertise a particular topic, or chapters to review, and they report back
3 to the Committee, and as needed risk important topics are scheduled for
4 briefing.

5 Although this does reduce the number of meetings required,
6 as well as the number of briefings from the applicant, and the staff, we believe it
7 does not adversely affect our safety mission. As you may recall, during the
8 phase four review, we identified issues such as the boron dilution issue that led
9 to changes in the design, as well as instrumentation set point settings.

10 The approach does offer the ability for reductions in the
11 schedule for the review. For example, our review of the Kairos Hermes
12 application was completed last month, four months ahead of our scheduled due
13 date with NRR, and yet, as you'll hear today from Member Petti, we still were
14 able to identify several significant safety considerations that were not present in
15 the initial application, or in the draft SC that we reviewed from the staff.

16 Slide five lists reports that pertain to the LWR operating fleet.
17 These reports address topics related to digital I&C, new fuel types for PWRs,
18 water sources for recirculation cooling, and a subsequent license renewal
19 application. In the case of the Oconee SLR application, there were no findings
20 in the staff review, **or** open items, or confirmatory items in the staff review.

21 So, we applied a streamlined approach that only required
22 briefings from the staff, and the applicant in a single meeting. The last letter
23 report was actually a one paragraph transmittal letter for a white paper that our
24 senior technical advisor prepared, regarding Dr. Hossein Nourbakhsh, to be

1 prepared regarding historical, as well as recent contributions from ACRS during
2 our reviews.

3 I asked Dr. Nourbakhsh to provide this white paper as a
4 knowledge transfer effort to new members, and other interested stakeholders,
5 and I think that it has some very significant findings. In the next slide I wanted
6 to highlight some other ongoing review activities. As indicated in the first bullet,
7 we have initiated interactions regarding several design center applications.

8 As you may recall, during our June 2022 briefing, I mentioned
9 that the ACRS reorganized in January 2022, and we assigned a lead ACRS
10 staff member to be associated with each of these applications, as well as other
11 applications we anticipate for the first year. That lead member, along with an
12 ACRS staff member hold informal meetings periodically with the NRR staff so
13 they remain cognizant of the progress of that application.

14 And they report back to the ACRS, and we schedule meetings
15 as appropriate on what topics we believe will be important with respect to risk,
16 and safety significance. Ultimately as more of these applications as well as
17 others transition from the pre-application stage to the application stage, we
18 envision that we will again divide ACRS up into two teams as we did back
19 during the nuclear renaissance era around 2010, or 2011 so that we can still
20 accomplish our mission without adversely affecting schedule.

21 And the last two slides, I'd like to discuss some other ongoing
22 ACRS activities. And as in prior briefings, I'll start with our continuing efforts to
23 transform, or initiate process improvements. In addition to knowledge transfer,
24 we are starting to develop, or continuing to develop guidance that promote best

1 practices for ACRS on conduct of subcommittee meetings on letter writings.

2 And most recently, we're starting to develop best practices for
3 conducting design centered reviews. And we believe that this facilitates
4 communicating not only us scheduling, and emphasizing what's risk important,
5 but also in communicating to NRR staff on what our plans are for the reviews.
6 We are continuing -- it'd be good to see the slide for a minute -- other activities,
7 such as -- I'm sorry, the prior slide, please.

8 We are continuing other activities to streamline, and focus our
9 reviews on risk significant items. For example, in recent times, you may have
10 noticed that instead of letter reports, we're emphasizing our findings in
11 paragraphs that are provided in our meeting summary reports, because we find
12 it's more important to focus on those letters that are risk significant.

13 And then in the last slide, we are continuing other beneficial
14 activities. We continue to hear from the staff on their transformation efforts, and
15 provide comments as appropriate. We are resuming our visits to plant sites, as
16 well as fuel fabrication facilities. Last summer we visited region three, the
17 Byron plant, as well as the SHINE construction plant.

18 We find that these visits are extremely important, because
19 they help us better understand the health of the facility, as well as interacting
20 with the staff, so that we can better understand their concerns, and priorities.
21 And at last. Oh, I also wanted to mention too that in addition to our knowledge
22 transfer, our reorganization, and revising our approaches for conducting our
23 reviews, we're also looking at to make sure that we have adequate expertise in
24 our membership.

1 So, we do appreciate your efforts to help us bring Dr. Martin
2 on board. And then last, I did want to mention briefly that we did complete our
3 international activity with representatives from advisory committees that support
4 regulatory agencies in Finland, France, Japan, and the United Kingdom. At this
5 time we are in the process of compiling a report that includes the presentation
6 materials.

7 As well as summarizing some of the discussion topics, and
8 key findings from that interaction. And that completes my planned remarks, and
9 I'd like to ask Member Ballinger to begin his presentation.

10 DR. BALLINGER: Thank you, Chairman Rempe, and good
11 morning, folks. First slide, please. I'm going to give a discussion of the SHINE
12 application review. The SHINE submitted an application in 2019, middle of
13 July, and they asked for 30 year license, and we completed the review in
14 December 2022 using roughly the same format that Chairman Rempe has
15 described. Next slide. please.

16 With regard to the facility characteristics, the facility is
17 designed to produce moly-99, which I'm sure many people in here know that if
18 you're over 65, or have had heart surgery, present company included,
19 technetium-99 is very important for the national medical infrastructure. So, it's
20 produced, again, from fission produced moly-99, which in this case is actually
21 fusion fission produced moly-99 from accelerators.

22 Which is probably the first instance of actually generating
23 fusion power, hopefully not the last. And the production facility consists of this
24 irradiation facility, plus an extraction facility, it's a two component system where

1 the moly-99 is separated from the fission products. Next slide. The SHINE's
2 unit, the SHINE facility has a lot of safety features which make it both safe, and
3 unique, if you will.

4 Low power density irradiation units accelerators, automatic
5 shutdown of the irradiation process, they're accelerators that can just be turned
6 off. And criticality is avoided, or not only avoided, but excluded during
7 dissolving filling on the radiation side, and criticality safe vessels are used for
8 the entire facility, as well as engineering design features.

9 Next slide. So, as part of this process, we had a number of
10 subcommittee meetings, six to be exact. We had several 19 chapter topic
11 memos as Chairman Rempe has described, and we had a site visit in
12 Janesville. Chairman Rempe has emphasized the importance of these visits.
13 This visit was for me, very important, because first off, this is kind of a one off
14 facility, it's unique.

15 It's the first time we've been to visit one of these things, and
16 we get to talk to people that were both actually the president of the company,
17 plus the lead design engineer, and the lead technical person, that's the way I
18 would describe them. And you get a really good feeling about these guys
19 having a good handle on their topic, and on their design.

20 So, I can't more emphasize the fact that these site visits are
21 very important. Next slide. By way of the safety analysis approach, the SHINE
22 people used what's called a maximum hypothetical accident. What they
23 basically did was to do a failure modes and effect analysis to identify every
24 scenario that could cause an accident, then use that analysis to define a design

1 basis accident, and then deal with that.

2 So, that was their process, and it worked quite well. Next
3 slide. As part of our review, again, visiting the site was very important. We
4 realize the importance of human factors in the facility. This is going to be a
5 facility where there's a lot of repetitive things going on, and so there's often
6 times a problem with repetitive action where you get kind of complacent.

7 So, we needed to understand that process. The coordination
8 with the community was also very important, because there's an airport that's
9 within walking distance of the site, and the site is going to make use of fire
10 departments, local organizations, and they really need to have a very good
11 understanding of what they're dealing with if there's a need for their service.

12 And last, but not least, there's an increasing importance of
13 cybersecurity, and so we got a chance to talk to them about that. But that is
14 considered to be important. Next slide. Based on our analysis, and our visits,
15 and the like, we concluded that the operating license should be issued. Next
16 slide. Okay, some lessons learned.

17 Again, as I keep reciting this, but it's true, as Chairman
18 Rempe has emphasized, the grouping of these chapters requires close
19 coordination between us, the staff, and the applicant to make sure that we don't
20 have a situation where there's kind of bleed off into other areas that we haven't
21 discussed beforehand. So, it's important to coordinate things very well that way.

22 And that, also the importance of sequencing the review with
23 no open items. We haven't emphasized that in the past, but this is a case
24 where we've had no open items, and that puts the burden both on us, and on

1 the staff to make sure there's no open items. In the old approach, there were
2 open items, and that kind of allowed for a little bit of slack in the system, but not
3 so in this case.

4 That required, again, committee flexibility. We had to sort of
5 adjust things on the fly, which we succeeded at, and this idea of having
6 individual members conduct a detailed review, and then have a discussion with
7 the overall Committee, that is not new, we started that with NuScale, but we
8 advanced that with this thing, with this analysis, and that's proven to be very
9 important.

10 Next. I think that's about it. That sure is about it. So, I will
11 turn over the presentation to Walt Kirchner.

12 DR. KIRCHNER: Thank you, Ron. Good morning, I'm going
13 to talk to you about our review of the NuScale methodology for establishing
14 EPZs, emergency planning zones, for NuScale SMR plants.

15 Next slide, please. So, I think this is common knowledge
16 background. Generally, EPZ sizes for nuclear power plants are defined by a
17 plume exposure pathway, and that's roughly ten miles in radius, and an
18 ingestion pathway area of about 50 miles in radius.

19 The basis for this was developed back in the 70s in a NUREG
20 report 0396, and its primary objective was to provide guidance for citing, and
21 development of emergency plans at then existing plants, and future plants,
22 such as to produce dose savings for a spectrum of accidents that might result in
23 exposure in excess of the protective action guidelines.

24 Next slide, please. So, there's an appendix to NUREG-0396

1 that outlines basically the rationale that was used to come up with this generic
2 ten-mile radius, and that was a -- I'll choose my words carefully here. Again,
3 we're talking about a generic ten-mile radius, and basically they recognized the
4 need for establishing defense-in-depth, because that's when emergency
5 planning is your last line of defense.

6 And in doing this they looked at a spectrum of accidents for
7 the operating fleet at the time, and then they made use of the analysis in
8 WASH-1400, which was just completed a couple of years earlier to look at
9 severe accident sequences as well.

10 Next slide, please. So, we have existing provisions in the
11 regulations for the plants, and we also have an exception, so to speak that
12 allows for a case by case basis for setting the EPZ for gas cooled reactors.

13 As well as reactors less than 250 megawatts thermal, what
14 we're calling SMRs in current parlance. Since that time, '78, when this was
15 done, there have been really significant advances both in the knowledge base,
16 the code methods that we use, and of course, unfortunately post Fukushima,
17 the actions that came out of that, as well as the SOARCA study, that's the State
18 of New York Reactor Consequences Analysis.

19 And so this concept, the concept that I'm going to talk about
20 now in more detail of looking at sizing an EPZ based on consequences of dose,
21 and then correlating a distance with the dose, such as to meet the protective
22 action guidelines, was explored by your staff, and that was documented in
23 SECY-11-0152. The industry picked up on that, and NEI developed a white
24 paper in the following year that also examined this.

1 And some of the things that were recommended in the
2 industry white paper are interesting here. That you would use the plant specific
3 PRA to inform the analysis, and that you would also supplement this with an
4 operationally functioned mitigation capability, which most of the plants post-9/11
5 have installed.

6 Next slide, please. I'll go more now to the NuScale
7 methodology. Again, it follows the same basic approach that was used in 0396.
8 It requires a full-scope PRA that meets the current standards, and looks at both
9 internal and external events, and all modes of operation. So, all modes, in my
10 parlance, is a euphemism for spent fuel pools and other aspects of plant safety.

11 They take advantage of RELAP and MELCOR tools to
12 develop their source term, and then they use the MELCOR MACCS code for
13 the actual consequence analysis. So, the MACCS code basically does the
14 atmospheric dispersion, estimates the doses, and you can go through a number
15 of sequences with that, and develop a family of dose exposure curves. The
16 approach is very similar to what we reviewed for the Clinch River Early Site
17 Permit. And it meets the intent of SECY-20-0045, and the draft rule for SMRs.

18 Next slide, please. Okay, so the criteria that are used, you do
19 these analyses, and the criteria that is used to actually set that distance for the
20 plume exposure pathway is based on three checks, if you will, and these are all
21 conservatively implemented by NuScale. You first look at your design basis
22 source term, and do your analysis, do that release.

23 And then look at what that distance is to an exposure of
24 essentially one rem total equivalent dose exposure. Then you subsequently

1 look at less severe accidents. So, usually what we're talking about is for LWR
2 system, the containment is intact, and you look at a sequence of accidents
3 there. Again, using this PAG criterion of one rem, and you'll come up with a set
4 of distance versus dose results as well.

5 And then for the more severe accidents, now, at least for
6 LWR technologies, we're looking at containment bypass or failure, you then
7 look at an acute body dose of 200 rem. And when you complete these
8 analyses, effectively, it's that last criterion that sets the plume exposure
9 pathway, and hence the EPZ size analysis.

10 So, in the case of NuScale, they also looked at multi-module
11 effects, where you're concerned about common cause initiating events for the
12 modules, as well as where the systems are connected.

13 So, that analysis was also done to take into account the multi-
14 module aspects of the NuScale design. The staff did an excellent job in
15 reviewing this, a very thorough job, and there were several conditions put on
16 the application of the NuScale TR methodology. NuScale used a proprietary
17 screening threshold for seismic events. Now, for this design, it's likely that a
18 seismic initiator is going to be the dominant contributor to the risk profile.

19 So, the staff, when they completed their review, they put
20 several conditions, limitations on the use of the TR. The first was they limit the
21 screening threshold to sites where ground motion response spectrum is
22 bounded by NuScale certified seismic design response spectrum, this just
23 makes good sense by the way. And then secondly, they limit the seismic event
24 screening threshold to the NuScale's high confidence of the low probability of

1 failure for plant level fragilities, so called HCLPF.

2 And when this TR is used at an actual site, then they will
3 require that the COL applicant do a confirmation that the ground motion
4 response spectrum, and HCLPF plant level fragility limits for that site are
5 confirmed for the as built plant.

6 Next slide, please. So, in summary, this NuScale
7 methodology is certainly technically sound, and I would add, conservative in its
8 approach, and its application.

9 The staff's evaluation as I mentioned previously, was quite
10 good, and they explored things like cliff edge effects, which is something one is
11 concerned about when you're looking at seismic analysis of power plants. And
12 we felt that the staff should preserve the insights gained from this exercise, and
13 use that in other applications, where again, the seismic aspect of the accident
14 spectrum may be the dominant contributor to risk.

15 We look forward, and plan to review an initial application of
16 the TR for an actual site, and I'll just summarize by saying that prudent
17 emergency planning, and preparedness will still require the staff looking at each
18 applicant on a case by case basis. And especially when we get to advanced
19 reactors, we're going to have different technologies, you're going to have
20 different hazards.

21 So, it's not like this is just turn the crank, here's a number,
22 you've got an EPZ. There are a lot of considerations that go into that kind of
23 analysis, and what comes with that too is that you're looking for on site, and off
24 site emergency plans that can deal with the hazards that the technology

1 presents.

2 And I will note, just one footnote to this summary is that going
3 back to the NEI white paper from 2013, they recommended to address
4 uncertainties, and the potential lack of completeness in the PRA, especially for
5 a new design, where we don't have the operating experience that we have with
6 the current fleet, that the emergency planning provide for expansion of the
7 existing emergency response plans beyond the EPZ boundary.

8 And that's just, in my mind, I think a prudent extension of this
9 methodology. And with that, I'll turn to my colleague Dave Petti.

10 DR. PETTI: Thank you, Walt. So, I'll first start by talking
11 about Part 53. In terms of background, as you well know, there are two
12 frameworks. Framework A builds on the industry DOE sponsored licensing
13 modernization project. Framework B resulted from industry comments for the
14 need for a more traditional deterministic approach to align with other
15 international approach like the IAEA's approach.

16 An important consideration that I'm sure we'll get to when we
17 get to Q&A, at least in my mind, is that any approach needed to demonstrate an
18 equivalent level of safety with what we have today, Part 50 and 52. I will go
19 through, there's two letters we wrote on this since we last met. The scope is, of
20 course as you know, incredibly vast. I'm going to focus largely on the last letter,
21 and the staff responses.

22 And how they responded, it's in blue text to help. I will not talk
23 about the reg guides that we reviewed with the final package in December, just
24 given the limited time that we have today.

1 Next slide, please. So, in terms of findings, and
2 recommendations, we thought that the rule package, and the associated
3 guidance were adequate to solicit public comments.

4 We found framework A to be a valuable, logical framework.
5 It's a flexible, technology inclusive, performance based regulatory pathway for
6 both LWS, and non-LWS. It is risk informed, it's consistent with LMP, and in the
7 vernacular, you'll hear PRA in a leading role. Next slide. Framework B we felt
8 was newer, and still evolving, and significant changes could still occur, and they
9 did from our letter last July, I think, and in December.

10 There were substantive improvements over previous drafts.
11 They took a risk informed performance based approach for siting, and for
12 seismic design criteria, and seismic design, and that's a big cost driver, and
13 doing that in a risk informed way is going to be really helpful for folks that have
14 to design the plants. There are technology inclusive requirements for fire
15 protection in the additional licensing basis events, sometimes called the beyond
16 design basis events.

17 There is now a lot more common language with framework A
18 on human factors engineering, staffing, operator licensing, and training, so all
19 good improvements we thought. Next slide. With the package that we
20 reviewed, it starts with the December letter, there was the preamble, formally
21 known as the statements consideration. We felt important to talk about it,
22 because it really gives you the rationale behind the frameworks.

23 Without it, you just can't understand the depth, what's really
24 going on, and why things are the way they are. It provided at least to me, a

1 much clearer understanding of the depths, and the differences of the two
2 frameworks. There were people talking about how to combine, A, and B are
3 two different philosophies essentially, they're like oil, and water, they really don't
4 mix.

5 We had that same argument when we first started, well why
6 can't you combine them? It's when you read that preamble that it just jumps out
7 at you about how different they really are fundamentally. It gave valuable
8 context relative to assuring that a technology inclusive, performance based
9 framework that is framework A yields the comparable level of safety to the
10 existing regulatory requirements.

11 Next slide. So, the preamble spent some time talking about
12 this evaluation of equivalent level of safety for framework A. Framework B is
13 just what we have in a technology neutral mode, but it was different enough that
14 they felt they needed to do this. They noted that it's very similar to the
15 integrated assessment of plant risk using principles of integrated risk informed
16 decision making found in Reg Guide 1.174.

17 All the requirements in framework A were cross walked
18 against the existing set of requirements to make sure there were no gaps, or
19 holes, and then industry performed tabletop studies on a variety of advanced
20 reactor designs. They did gas, they did sodium, they did heat pipe, and a
21 molten salt one was done, it may not have been part of the official study, but I
22 remember reading a report, they looked at it.

23 I think the results indicated the approach is flexible, and
24 workable, it didn't set a higher regulatory bar for safety, and it showed a way to

1 incorporate risk insights into the design, and the regulatory review.

2 Next slide. In terms of AERI, the alternative evaluation for
3 risk insights, we really liked it. We had made an earlier comment about a
4 graded PRA/risk approach should be considered, typically in light of
5 microreactors, and I think that's really what AERI is about. So, we liked it so
6 much, we said, gee, it would be nice if it could be made available under 50 and
7 52, like the LMP is available today under 50 and 52, that was sort of the
8 thinking.

9 We also recommended a tabletop exercise should be
10 performed, that was sort of a recommendation for industry, obviously, and us in
11 tabletops. The language was a little unclear on this term self-reliant mitigation
12 facility, which is really important for how involved the reactor operator is to
13 execute a safety function, or not, and it needed to be somewhat more
14 consistent with the interrelationship with AERI, there was just some wording.

15 And the staff did improve the definition, and clarified that the
16 entry conditions, and the need for operator action were separate concepts, so
17 that was good. The next slide we made a comment that the rules should
18 explicitly mention that there will always be a human being maintaining oversight
19 of the reactor, providing a last line of defense independent of the design
20 features.

21 And the staff stated in the reconciliation letter that
22 performance based demonstrations, and prescriptive minimum requirements
23 would serve to ensure that there's always operating staff overseeing facilities.
24 Next slide. We made a comment on the discussion of defense-in-depth. It

1 should be amplified to address more explicitly what's the role of inherent, and
2 passive characteristics in accident prevention, and mitigation.

3 There is a difference in the balance between accident
4 prevention, and mitigation with the existing fleet versus non-light water reactors.

5 There's much more in the accident prevention camp. So, how does that evolve
6 in your thinking, and how defense-in-depth is thought about in the entire
7 approaches, because it's a lot, it's through all of our regulatory fabric.

8 And again, these safety characteristics, these inherent, and
9 passive characteristics may have to be relied upon in combination with
10 engineering, judgement, and data from the robust startup program to really
11 compensate for the lack of operating experience. Staff agreed with this
12 recommendation, and they anticipate some guidance. So, that's good, I think
13 that will really help here.

14 Next, there was improved discussion of safety functions,
15 they're very explicit in the top down approach of framework A. But in framework
16 B they're implicit through the safety design criteria, and the staff told us they
17 anticipate changing Reg Guide 1.232 to align the design criteria to the relevant
18 safety functions for framework B. So, that logical flow that you see in A will also
19 be available in B, and I think that'll help clarify things.

20 We commented, I think more than once on trying to
21 streamline the rule. Although it is shorter than Part 50, or 52 individually, it may
22 still be too long relative to expectations of stakeholders, and there is this trade-
23 off between clarity and overall rule length that we've heard about from many.
24 And the staff continues to look for areas to streamline, and they did in

1 framework B, streamline some things in the last draft that we had seen.

2 Next slide, additional recommendations here. Manufacturing
3 licenses, there's large changes in the rule language here, a new licensing
4 pathway obviously for some of the microreactor designs, but we felt at this point
5 to make sure to exercise some prudence while more experience is gained.
6 This is something we just don't do on a routine basis.

7 In terms of the facility safety program, we liked that it was
8 going to improve the efficiency of NRC's licensing, and reactor oversight
9 programs at the individual facility level, and should consider its use in B, as well
10 as A. The integrity assessment program, this is words about looking for
11 degradation of SSCs, building, and life, especially in view of the experience in
12 the light water fleet.

13 Where water seemed like it was not going to be very difficult,
14 and it's turned out to be a pretty difficult coolant to make sure you don't get
15 stress corrosion cracking, and the like. And now you've got these new
16 coolants, and so we thought that that was a valuable program to add to Part 53,
17 recognizing that there are things like section 11 of the ASME code, I'm sure
18 there'll be good guidance to make sure there's no overlaps, and duplications.

19 Next, safety classification. We reiterated in our letter,
20 because it was in a previous letter, we're concerned the historical process of
21 classification resulted really in too many systems being classified as important
22 to safety, but later found when you had the PRA, to not have major risk
23 significance. So, our goal was really to try to optimize the safety footprint in the
24 design.

1 And this would have major benefits for both the licensee, and
2 the regulator, keeping the focus on the risk significant components, particularly
3 with the new technology, where you don't know is that important, is that
4 important, or is this more important than that? You just don't know with the little
5 operating experience, and the staff agreed with the concept, and felt that the
6 classification systems were adequate.

7 Next is the concept of generally licensed reactor operators.
8 Lots of engagement on this, went through a lot of iterations, but we generally
9 now support the concept where there's a certain adequate level of qualification
10 for different types of facilities, depending on what the role is of the operator.
11 The staff improved the clarity of the definitions, and the tie between that self
12 mitigation facility definition, and the GLRO.

13 But looking ahead, we felt it's important for both the licensee,
14 and the GLRO to realize the weight of the certification decision. In the current
15 fleet, it is a big deal. There's a little ceremony, and NRC is heavily involved,
16 and it rests on their shoulders because of the role of operators in operating the
17 current fleet.

18 But the licensees now would own that responsibility, and they
19 have to diligently ensure certification requirements are met. And then the NRC
20 inspections must be thorough, and frequent enough to ensure effective operator
21 qualification programs to let the GLRO know look, they're still here, we're still
22 looking, come two years after you got your certification, this kind of doesn't
23 have the same impact.

24 So, let me talk a little bit in closing. Industry has provided

1 comments in our meetings about their concerns in Part 53. Some industries
2 support Part 53, some do not. Achieving full consensus may not be possible.
3 In my opinion, there's a lot about balance here. There's a lot of flexibility that's
4 given in framework A for instance, which is really good, but with flexibility comes
5 responsibility.

6 And I think you have to balance that, and that's really what the
7 staff has been trying to do, I think. There are valuable pieces of Part 53 being
8 used by non-LWR applicants today. The reg guides that basically endorse
9 LMP, huge step forward, I think every single advanced reactor applicant that
10 Chair Rempe showed in that slide this morning, we asked them explicitly, they
11 are using LMP.

12 Which in a sense means they're using the heart of framework
13 A. In addition, we think the two new draft reg guides, which I didn't talk about
14 here, the one on how you identify accidents, which is in response to use talking
15 about the need for having some good guidance, and the AERI approach could
16 also be extremely valuable, and to make sure that we don't forget about those
17 reg guides, that's important.

18 Now let me turn to Kairos, and the construction application
19 permit for Hermes. Next slide. Before we get into it, Chair Rempe mentioned it,
20 but this letter, the structure of it reflects our evolving approach for advanced
21 reactor reviews. It builds on NuScale, and SHINE, but it's got a more top down
22 focus. It starts with a little bit of what the reactor is, does, looks like, but then
23 what are the novel features?

24 What are the key safety functions? What are they, how are

1 they implemented, how do they work, how do you know they work? What are
2 the principle design criteria, the classification of the components that have to
3 meet those criteria, and how is defense-in-depth implemented in the design?
4 Then into sort of the heart of the safety analysis, the postulated event selection.

5 Safety analysis, and particularly the safety margin, that's
6 something we're looking for, given these new concepts shouldn't be designed
7 right to the edge, there should be some margin. And then are there any issues
8 in the operational reliability realm, worker safety, and at least at a construction
9 permit stage, is there any technology that has to be developed before you get
10 to the operating license?

11 So, that's the way the letter was structured, and that is the
12 way we hope to structure all of our letters. They might not have all of these, but
13 it's kind of a punch list for us how to think about the problem going forward.

14 Next slide is a schematic of the Hermes test reactor. It is a
15 pebble bed reactor using molten salt FLiBe as a coolant. That inner orange-red
16 area is where the pebbles are. They come in through a chute in the top of the
17 reactor, down through the graphite, and enter at the bottom of the core by the
18 fueling chute. There's graphite, there's a reactor vessel. The blue is the decay
19 heat removal system that sits on the outside of the vessel, so in the event of
20 loss of circulation, heat is radially transferred through the pebbles, through the
21 FLiBe, which undergoes natural circulation to the vessel.

22 And then to the system with water is in at sort of an ultimate
23 heat sink. Next slide. So, what are the novel aspects? This is the first reactor
24 application of functional containment. We've seen it in many DOE fuel cycle

1 facilities, SHINE actually kind of uses functional containment, but this is the first
2 nuclear reactor application. It's also the first application of what's called Div 5,
3 ASME Section 3 Div 5 developed for high temperature materials.

4 DOE spent a lot of money on getting these materials
5 approved, and in the code, and it's good to see people actually using it. You
6 couldn't design this reactor without it. The pebbles, and the graphite are
7 buoyant in the FLiBe, so they float, and that provides some really interesting
8 design challenges in the design. The pebble here is different.

9 It's not a classic German, and now Chinese high temperature
10 gas reactor pebble. It is small, it's about the size of a marble, and the fuel
11 pump TRISO particles are in an annulus in the middle of the pebble. Because
12 in the German pebble, they're everywhere, except there's an outer line that has
13 no particles, so here's those differences.

14 There's anti siphon features to limit the loss of coolant
15 inventory in the event of a pipe break. So, basically you can only lose so much
16 FLiBe, and then it just sits in the vessel, so it's always there, if you will. There
17 are what are called fluidic diodes to enable natural circulation when the forced
18 circulation is lost. And then you've got to handle these pebbles.

19 They come out, they get scanned to see if they're fully
20 burned, and if not, they go back in. So, all of that is new, relative to say light
21 water reactors. Okay, next, in terms of our conclusions, and recommendations,
22 we said that the key attributes of the design are the low thermal power, the use
23 of TRISO fuel, and FLiBe coolant as an effective functional containment, and
24 the passive heat removal capability.

1 I changed color there, because that means there's another
2 slide coming on that in a little bit more detail. The overall design results, and
3 projected dose consequences with large margins to regulatory citing criteria.
4 And this allows us a unique approach to safety classification components that
5 we'll talk about in a couple slides. Next slide, so what are the safety functions?

6 Limiting release of radionuclides, they use functional
7 containment. Controlling heat removal, as I mentioned earlier, it's transferred
8 by conduction through the fuel pebbles, natural circulation of the FLiBe, and
9 conduction through the vessel. Fluidic diodes to help natural circulation, and
10 the passive heat removal has four independent trains, three of which can
11 remove heat, and testing is planned to verify that it will work as advertised.

12 Controlling reactivity, there are two sets of control elements,
13 four elements in the reflector to control the reactivity, and three shutdown
14 elements that go into the pebble bed to shut down the reactor. Only two of three
15 shutdown elements are needed to accomplish reactor shutdown. Testing is
16 planned to confirm their operation, and behind that is a very strong inherent
17 negative temperature coefficient of the fuel coolant, and moderator.

18 So, some defense-in-depth there. And finally, for any of these
19 safety functions, no AC power, or operator actions are needed to mitigate any
20 design basis event.

21 Let's turn to functional containment. Two inherent robust
22 barriers: TRISO fuel and FLiBe. This unique combination results in very small
23 source terms. Even with Kairos assuming fuel failure 100 times greater than
24 measured in the DOE TRISO fuel program, projected doses are still 100 times

1 below the citing criteria. And the doses are not dominated by fission products;
2 they're dominated by tritium generated from the FLiBe and argon-41, which is
3 from activation of the air trapped in the graphite porosity and in the cover gas.

4 Next slide. So, now let me talk a little bit about this functional
5 containment, and what it can get you, and how it helps you with safety
6 classification. So, the reactor vessel is a safety related item, but the piping in
7 the design is not. Historical practice would say, and defense-in-depth would
8 say you should make that piping safety related. Safety analysis takes no credit
9 for the piping.

10 The FLiBe does not chemically react with the air, so the
11 piping doesn't prevent a chemical reaction like in sodium reactors. And then
12 there are these large margins, so which way do you go? Do you go with the
13 historical precedent, or do you do something different? And in this case, we felt
14 the safety margin outweighed the historical practice, but this would be done on
15 a design specific basis.

16 We highlight this here, and put this little box at the bottom of
17 the slide. We think we're going to see other types of departures like this, and
18 the staff SCs sometimes don't really get into some of this rationale, it's just not
19 what they do in the NSCs, but we think it's important for the public to
20 understand that we've gone through, we understand the rationale. Nobody is
21 cutting corners here, and explain that.

22 And this is one of these things with advanced reactors that
23 you're going to see, we're going to see more of in different cases. Next slide.
24 We said because of the first of a kind nature of the FHR technology, there are

1 performance uncertainties that can really be best addressed during operation of
2 the reactor itself. The scaled demonstration plant like Hermes will be very
3 valuable to test the technical elements, design features, the safety functions,
4 and the equipment performance of the technology.

5 The key concern that we raised is how is the beryllium,
6 airborne beryllium, and tritium in the facility going to be managed to stay below
7 the relevant regulatory limits, and protect the safety of the workers. This is not
8 an issue at the CP stage, it's more the OL stage, but we felt it had to be in the
9 letter, because it's the key thing in this technology that we have to keep an eye
10 on.

11 So, what are some of the performance uncertainties? To
12 control what's called the chemical potential in the salt, this is to make sure you
13 keep corrosion well under control. In presence of neutrons, and in a
14 temperature gradient where you've got the hot outlet coolant, and the cold inlet
15 coolant, this theoretically looks doable, but has not been demonstrated in a
16 system such as this.

17 FLiBe, if you move off the eutectic composition, the viscosity
18 can change, it can turn from water to molasses, so you've got to control it in a
19 window. Can you control it in an engineering sense? This is something that
20 we'll learn from the operation of Hermes. What are the level of impurities that
21 you're going to see in the salt, and how do they affect fuel performance?

22 TRISO fuel is particularly susceptible to silicon carbide attack
23 by metallic impurities. The chip industry is worried about this, TRISO people
24 are worried about it, and again, you won't know until you actually operate it. In

1 addition, one of the issues that we raised was there is uranium that comes in
2 the beryllium fluoride that's part of FLiBe, it comes out of the earth when you
3 mine it.

4 And so, you're going to fission that uranium, and you'll get a
5 mixed waste. And in the old molten salt reactor experiment, disposition of that
6 salt was extremely difficult, but it had a lot more uranium. And so, we asked the
7 question, well, have you looked at this? And they assured us that they had,
8 and that they have disposition path, which was good, because that would be
9 really important for the technology.

10 Next slide. As noted in the staff SC, there is confidence that
11 this facility can be constructed in accordance with the relevant regulations, and
12 the design basis that's outlined in the SAR. There are still detailed design
13 analysis, and technology qualifications that will need to be completed prior to
14 the operating license review, and we'll have a list of those in the next slide.

15 One thing that was not talked about by the staff was
16 combustible gas generation associated with graphite oxidation. This is not
17 hydrogen, this is carbon monoxide, and so we felt that should be included in
18 evaluations going forward. And that we felt that the construction permit should
19 be approved. In terms of what's the punch list of things left to confirm the
20 adequacy of the design of these SSCs.

21 Fuel pebble behavior, the experiment's planned on the wear
22 of the pebble, graphite dust. FLiBe infiltration into the porosity, of that happens,
23 that could be a bad day. There's a number of tests relative to the high
24 temperature materials, and the graphite qualification surveillance that they plan,

1 oxidation of graphite. We know a lot about oxidation of different grades, this
2 specific grade hasn't been studied as much.

3 Validating the computer codes, developing this fluidic diode to
4 make sure that it'll work. Justifying the thermodynamic, and vapor pressure
5 correlations that are used to calculate the source terms, and developing the
6 sensor technology for the chemistry is also very challenging here. Something
7 that will work for as long as the reactor plans to operate.

8 Kairos is committed to finishing these before completion of
9 construction, and the staff has noted these items in their review. They have
10 something called Appendix A of the SC, it's kind of like their punch list. So,
11 everybody is sort of aligned, and it's good to see that we've got that list. And
12 with that, I will turn it back over to Chair Rempe.

13 DR. REMPE: Thank you, Dave. This completes our prepared
14 remarks, and we'd now like to welcome questions from the Commission.

15 CHAIR HANSON: Thank you, Chair Rempe. We're going to
16 begin this morning with Commissioner Crowell.

17 COMMISSIONER CROWELL: Thank you, Mr. Chair, thank
18 you Dr. Rempe, thank you to all the ACRS members who are presenting today,
19 and are here as well. In my short time at the Commission I've enjoyed our
20 interactions, and getting to know all of you, and the important role that ACRS
21 plays. Actually going forward would like to see you guys more regularly at
22 some more routine meetings we do, rather than just once a year, so maybe we
23 can work on that.

24 A lot of questions, I'm going to try to pepper all of you with

1 some of them with my time I have here. But Dr. Rempe, I wanted to start with
2 you, and just I see the ACRS mission, and the value they play is critically
3 important for the NRC, and commercial nuclear as a whole, because it's the
4 belt, and suspenders approach that the NRC, and ACRS play is part of the
5 heart of maintaining, and building public trust.

6 So, we've just got to make sure we're doing our jobs well, and
7 we're doing them fully coordinated, but independent as well, and efficiently. So,
8 could you talk a little bit more about the process improvements that you guys
9 have self-identified at ACRS that you're hoping to implement going forward, and
10 particularly if there's any of those that maybe apply to NRC staff, that they could
11 adopt as well?

12 DR. REMPE: Thank you for your comments about ACRS,
13 and your question. I tried to highlight some of the process improvements in my
14 presentation today. The fact that we are working with this new evolving
15 approach, and conducting these design centered reviews, so that we have
16 reduced the number of meetings, and presentations by the staff, and the
17 applicant.

18 It does require that members are very proactive, and working
19 together with -- again, we have our ACRS staff member with us to preserve the
20 independence, but as well as the NRR staff. And I think it's working well.
21 Today I think I mentioned, I hope I did, that we did complete the Kairos review
22 four months ahead of the agreed upon schedule, and that takes close
23 coordination, as Member Ballinger indicated in the SHINE review, as well as
24 Dave indicated in the Kairos review.

1 We are trying to look for other process improvements such as
2 the way we conduct the SLR reviews, and then I think this guidance that we've
3 been working on is actually very beneficial, and I think as we move forward, that
4 that's where we're going to get the most bang from our bucks for trying to
5 improve things. Because if you look at the workload coming down the pipe,
6 there's a lot of these design centered applications coming through.

7 And the more that we can do to agree on the process for what
8 should be done, and get agreement from NRR staff with our, again, ACRS staff
9 present on how we'll conduct this, I think it'll be a more process oriented
10 approach where we hit, as Dave mentioned, the key points of what we expect,
11 and what we're going to be looking for, and everyone understands the ground
12 rules.

13 And I had mentioned that our guidance development effort
14 includes a Committee engagement plan, and we actually had a meeting with
15 NRR staff present, and discussed where we believe the status is, and the four,
16 or five projects that were discussed during that meeting this week, I think there
17 was agreement on -- we didn't hear any disagreement from NRR staff.

18 Maybe we'll hear something later, but yeah, this is where we
19 think things are coming in, and what we would expect for the upcoming review.
20 So, I think that's where we should focus in the near term to get the most
21 process improvements. Does that answer your question?

22 COMMISSIONER CROWELL: It does, and I appreciate that. I
23 will add, if you don't mind, on your behalf, that you're also looking to round out
24 the membership of ACRS, and with the goal of specific expertise so you can

1 handle an increased work load, and it's something that the NRC needs to be
2 focused on as well, the increasing work load, and having the right matching
3 expertise, so thank you for all of that that you do.

4 Dr. Kirchner, I think I want to talk about EPZs for a little bit.
5 When you are going to move to review of the NuScale combined operating
6 license, I believe you said that you're going to review that, are you going to
7 consider in the applicant both an ingestion pathway, and a plume exposure
8 pathway?

9 DR. KIRCHNER: The answer is yes. The focus of the
10 methodology of course was on plume exposure pathway, and that was what we
11 reviewed, and I presented today, but yes, that comes back with the actual COL
12 application, and of course the ingestion pathway is a much more site specific
13 set of considerations depending on obvious things, location, location, location,
14 and such.

15 But that same -- the existing rules that are in place, I think will
16 cover the proper review of the ingestion pathway considerations.

17 COMMISSIONER CROWELL: I know in your presentation
18 you mentioned the focus on seismic is a key safety parameter, something we
19 need to account for. Is that based on the technology's susceptibility to seismic
20 activity, or based on the presumed site selection?

21 DR. KIRCHNER: Well, it will be both. I think the technology
22 is pretty robust at this point, and also with this evolutionary LWR design, I think
23 what we're seeing is that the frequency of events is much lower compared to
24 the existing fleet when you start going through potential event sequences. The

1 dose, the source term is lower because the units are smaller, and that's almost
2 the linear kind of reduction, and the potential source term.

3 And the design characteristics, for example, the NuScale
4 design are such that the time to release also is a much slower process, so there
5 are a lot of things that are lining up in favor of doing that kind of analysis, and
6 allowing one to, with conservative assumptions, to pull back that EPZ boundary
7 definition.

8 COMMISSIONER CROWELL: Thank you, appreciate it. Dr.
9 Petti, talk about Part 53 for a quick second, I appreciated both of your
10 presentations, but I wanted to focus on Part 53. I appreciate the point ACRS
11 made last year about the balance of rule versus guidance, or formal regulation
12 versus guidance in the new Part 53 rule. I mean, I think you guys flagged that
13 in your early letter last year.

14 And since the Commission's had a chance to receive Part 53,
15 and have a meeting on it, I think all of us are now thinking about what is that
16 right balance between rulemaking, regulation, and associated guidance. ACRS
17 says that it probably should be done for a variety of reasons, including just for
18 general optics, and stakeholder support.

19 But is there a way ACRS could provide more insight on what
20 areas may be ripe for guidance, or work with staff on that as appropriate?
21 Because I think it'd be helpful if we're going to move in that direction, to have an
22 informed, and substantiated reason for why we're putting some things in
23 guidance, and others not putting them in guidance.

24 DR. PETTI: Sure, I think there's a way that we could do that.

1 We have seen an initial list of all the regulatory guides, and they're quite
2 extensive. What we haven't done is gone through them with the staff, and from
3 a risk perspective, say these look important, these don't. That's something that
4 we could definitely think about going forward.

5 COMMISSIONER CROWELL: I think it'd have a lot of
6 validation, particularly for the public, and stakeholders that we're thoughtfully
7 thinking about what should be in guidance, versus what maybe is not
8 appropriate. And not streamlining the rule for the sake of streamlining, but
9 doing it in an informed way.

10 DR. PETTI: To me the issue that I struggle with is sure, it's
11 easy to say put it in guidance. But if it's in Part 50 and 52, in the rule, you've
12 created now a difference, and that's a boundary condition, the staff said no, we
13 can't do that. So, many of the issues I think fall in that sort of category, where
14 changing it would open up that difference, and that has all sorts of ramifications,
15 I think.

16 COMMISSIONER CROWELL: It does, and I'll return my 30
17 seconds, and let that just hang out there for a while.

18 CHAIR HANSON: Do we need to take a moment of pause, of
19 reflection on that? I don't know. Thank you, Commissioner Crowell.

20 Member Ballinger, I wanted to start with you this morning.
21 Both SHINE and Kairos applications rely on NUREG-1537, which is the
22 guidelines for preparing, and reviewing applications for the licensing of non-
23 power reactors, right? Which uses deterministic approaches, such as single
24 failure criterion and maximum hypothetical accident, I think, which you've noted

1 in your slides, to evaluate SSCs and components. And NUREG-1537 doesn't
2 require use of risk assessments like PRA.

3 But do you see, potentially, I guess, a potential for broader
4 application of 1537 being applicable to power reactors that employ simpler
5 designs and passive inherent safety features?

6 DR. BALLINGER: Wow, that's a good question for which I
7 don't have -- I'd have to think about the answer to that. With respect to the
8 SHINE application kind of fell into the sort of grey area between risk-informed,
9 completely PRA-related, and deterministic. But the SHINE -- gosh, I hate to say
10 I'd get back to you on that, but I won't.

11 CHAIR HANSON: I thank you for your candor.

12 DR. BALLINGER: I think, yes, in some respects. I think so,
13 especially with the newer advanced reactors, where there's a clear, as Member
14 Petti has outlined, huge margins. I think that's my story, and I'm sticking to it.

15 DR. REMPE: If I could supplement?

16 CHAIR HANSON: Yeah, anyone.

17 DR. REMPE: One of the things that I think members were
18 very pleased with with the SHINE application is they did a qualitative risk
19 assessment, and they had a risk matrix. And when I hear some of the
20 discussion about you don't want to do a PRA, I think people too often focus on
21 a full scale PRA, and this simpler risk matrix is -- again, I can remember
22 Member Bley when he was still on the Committee, people need to think about a
23 simpler design could have a simpler PRA.

24 And this risk matrix was a great thing to see in the SHINE

1 application, and I personally was very pleased with it. And I think Member Petti
2 would like to jump in.

3 DR. PETTI: To me, the big difference in 1537 is the lack of a
4 requirement in the risk area. But I think you could do something, this risk matrix
5 comes from DOE, because they deal with so many different oddball facilities,
6 they've had to do a lot of thinking here that I think you could think about doing
7 that here. I also agree, I even think full PRAs on advanced reactors will be
8 much simpler than on the existing fleet.

9 This idea that it's a burden, we specifically asked the lead
10 person who developed the non-PRA standard that question to confirm what my
11 gut said. He said absolutely, there's fewer systems, there's fewer interactions
12 between systems. Water reactors are fairly complicated, water, water
13 everywhere sort of thing. Go ahead.

14 DR. BALLINGER: Recall, remember that in the rest of the
15 world, they use, they call it failure modes and effect analysis. To this
16 metallurgist, that sounds a lot like the initial part of a PRA, which is what they
17 did.

18 CHAIR HANSON: We have this concept of incorporating risk
19 insights, which is PRA, certainly related, but isn't necessarily the full-blown
20 thing, but is important for reviews. So, thank you, I appreciate that discussion.

21 DR. PETTI: I sometimes think the risk insights are the most
22 important. Calculating the number is not as important as getting those insights,
23 because they influence design, they influence how the regulator thinks about
24 things, those insights are really important.

1 DR. BALLINGER: Remember, 1537 was actually, there was
2 a modification to it for this application.

3 CHAIR HANSON: Okay, yeah, thank you. I had forgotten
4 that, appreciate that, thank you.

5 Member Kirchner, I wanted to touch on this EPZ, and you
6 said something that really caught my attention. I think it was there are a lot of
7 factors that go into the EPZ sizing, you don't just push a button and the number
8 pops out. And that's really, in my book, kind of the difference between being
9 kind of risk informed, and risk based.

10 And I wondered if you could just kind of say a little bit more
11 about not solely relying on quantitative results from some kind of PRA, or risk
12 based approach.

13 DR. KIRCHNER: Well, the advantage that, for example,
14 NuScale has, or any evolutionary LWR would have, would be to draw on the
15 huge operating experience that's out there with the fleet, with the equipment,
16 the components. We talked about failure modes and effect analysis. So,
17 you've got a much stronger base to deal with. But more to your question, as we
18 expect the advance reactors in general consistent with your policy, to -- Dave
19 mentioned this, be more reliant on inherent passive safety features.

20 So, we expect more margin, we expect that they'll be more -- I
21 used the word for NuScale, robust in terms of their design. I think the challenge
22 comes in in areas like for NuScale, if the seismic initiator is dominating their risk
23 profile, and now we're getting into a space that becomes -- has a lot more
24 uncertainty. The debate between the staff, and the applicant was pretty much

1 about how do you define the edge.

2 Where do you define the cut off, and in the end it's really
3 qualified engineering judgment that applies. So, that's an example where you
4 have numbers, and you basically have a fairly high level of confidence that this
5 is conservative, the result. But it takes that added engineering judgement, and
6 that's what I was trying to allude to when I said it will be on a case by case
7 basis. And then the other thing that we have to look at is are there additional
8 hazards.

9 And the proposed rule also requires you, and I didn't talk
10 about that at all today, but the proposed rule requires you to look at other
11 hazards off site that might impact the execution of your own emergency plan.
12 So, that's an example of additional consideration. So, it's just not enough to
13 turn the numbers, and come up with the -- the other challenge that I didn't
14 mention is that what we're likely to see, and we'll probably see this with
15 NuScale.

16 Is that the calculated result will be within the exclusionary
17 boundary of the plant. Now, when you come in close, now I'll get a little
18 technical, wake effects, and things like that become important in how you do
19 the dose analysis. So, 0396 was based on classic dispersion, weather
20 patterns, and so on. That works very well when you're looking at ten miles, and
21 you have all the history of the site, and you can factor that in.

22 Now when you're very close in, you have to look harder at
23 other things. For example, there are advanced methods for looking at close in
24 dispersal, and dose effects that are used to currently analyze the control room

1 dose. There's a code called ARCON that is often used for this purpose. So,
2 that doesn't directly answer your question, but there are a lot of factors that will
3 go in that go beyond just that calculation of the EPZ radius.

4 CHAIR HANSON: Thank you, I appreciate that. One last
5 question from me. Member Petti, I wanted to ask, the construction permit
6 application for Kairos doesn't include a request for authorization to possess
7 special nuclear material, and that's going to get addressed in the operating
8 license, obviously. But based on your review of Hermes so far, can you offer
9 any perspectives on the design from a material control, and accountability
10 standpoint?

11 DR. PETTI: The biggest issue is the storage of the pebbles, I
12 think. But if they're fully burned, they're not going to produce much of a risk
13 from proliferation. There have been many studies looking at TRISO particles.
14 When you go to these high burn ups, they're really not very attractive compared
15 to others. There's an argument over whether they're more proliferant because
16 it's a different fuel form.

17 I describe it as different compared to a fuel rod. I think if they
18 had anybody that could read things in the literature, if you really want to do it,
19 you could do it, I mean it's not that difficult.

20 CHAIR HANSON: Thank you very much. Commissioner
21 Baran.

22 COMMISSIONER BARAN: Thanks. ACRS plays an
23 incredibly important role in our licensing reviews, so thank you for your hard
24 work, and your valuable insights, I appreciate it. With an increasing number of

1 new reactor applications anticipated in the near term, there's understandably, a
2 lot of stakeholder focus on NRC's ability to review all the applications that come
3 our way, and to do so with efficient, effective, and timely process.

4 The agency has received a good number of suggestions for
5 how we can improve our processes, and some of those relate to ACRS. For
6 example, the Nuclear Innovation Alliance recently issued a report on ACRS with
7 some recommendations. Joy, I'd be interested in hearing your thoughts on the
8 recommendations.

9 DR. REMPE: Thank you, Commissioner Baran, for that
10 question. I am aware of the recommendations in that report, as well as several
11 other reports, or letters that have been provided by stakeholders recently that
12 do mention ACRS, and I do appreciate the opportunity to comment on them
13 today. I first want to say that I think I speak for all of the members in saying that
14 we are very receptive to suggestions for improving our processes.

15 All of us want to be as effective, and efficient as possible. In
16 the case of the NIA, the report that was solely on ACRS, I think that members
17 would agree generally with many of the suggestions, and recommendations in
18 that report. But I'd also note that we have identified many of those
19 recommendations, as well as received input from NRR staff, from applicants,
20 the Commission actually in the last several years.

21 And we, as I hope I communicated during my presentation
22 today, have taken actions, and made significant progress in reducing the
23 number of duplicative meetings, streamlining our review process, reducing the
24 number of reports, so that we can focus on risk important topics that we provide

1 the Commission. And again, we are continuing to try, and improve these
2 processes.

3 I'd briefly like to note that there's some misconceptions in that
4 report, perhaps due to a lack of understanding of our processes, our impact on
5 schedule, and our costs. So, I'd like to put a flag out there to say wait, don't
6 believe everything, because maybe there's some miscommunication there, or
7 some omissions there on the full aspects of what we've done.

8 And then finally I'd note that I personally have some concerns
9 about three of the recommendations in that report, because I believe that they
10 would adversely affect the schedule for the Commission to complete their
11 milestones, they might not be a wise use of agency resources, and then I have
12 a lot of questions about one recommendation that I believe might adversely
13 affect our ability to support the agency's safety mission.

14 I'm talking about recommendations to narrow the scope of the
15 ACRS review to novel aspects of applications that affect safety significance.
16 Today I think you've heard several examples where ACRS identified items that
17 were not in the initial application, or the staff SC affecting boron dilution, or
18 combustible gas generation for example. I'd note that these are not novel
19 issues, or new phenomena.

20 And I would question how, if that scope is narrowed, if we
21 would still be able to identify such issues. But again, I want to emphasize that
22 we do appreciate comments, and suggestions, and we are trying to improve our
23 processes. Does that answer the question sufficiently?

24 COMMISSIONER BARAN: Yeah, very much so, thank you.

1 DR. REMPE: Maybe more than you wanted to hear.

2 COMMISSIONER BARAN: No, that's great, I wanted to get
3 your sense of it. The Part 53 new reactor regulatory framework is obviously a
4 major focus for the Commission right now. We had a great discussion with the
5 NRC staff, and a panel of external stakeholders a few weeks ago. We've also
6 received five letters from the Committee, which I found very helpful.

7 I'd like to get your perspectives, either as a committee, or as
8 individual experts on some of the tough issues we're all grappling with. There's
9 been quite a bit of discussion about whether QHOs should be a cumulative risk
10 performance standard in the rule. The safety goal policy statement includes
11 qualitative health objectives, and quantitative health objectives.

12 What do you think about including the qualitative health
13 objectives in the rule, and the quantitative health objectives in guidance, or are
14 there other approaches we should be thinking about in this area?

15 DR. PETTI: The concern that I have is, I mean quantitative
16 QHOs have been around for a while, I could cite industry documents, the non-
17 PRA standard, I could cite Commission policy statements, other internal
18 documents. You need a cumulative risk metric as a requirement to close the
19 loop to say do you have the same level of safety as Part 50 and 52. Without
20 that, the staff may be required to have to implement some new requirements to
21 assure themselves that they have the same level of safety.

22 That said, I think there are many risk surrogates that could be
23 developed, because we outline one of ours, that we're concerned that the LWR
24 risk surrogates may not work for some of the advanced technologies. For

1 instance, the protective action guidelines. If you can meet the protective action
2 guidelines, you should implicitly have met the safety goals.

3 And the staff, I'm sure, could do the math, and prove that in a
4 way. So, I think there's some ways to prove it numerically. But without it in the
5 rule, and in a quantitative way, I think it is a hole.

6 COMMISSIONER BARAN: Okay. Any other thoughts on
7 that?

8 DR. REMPE: I just would note, that we have one member,
9 Member Bier, who has a passion about the safety goals, and again, it's not -- I
10 know the agency spent a lot of resources to come up with the safety goals. But
11 she's convinced the membership that it's worth us having some exploratory
12 activities where we periodically hear from outside experts about the history of
13 the safety goals.

14 And I believe that her underlying objective to see if there's
15 some insights that we might be able to gain. And I guess if it's acceptable to
16 you, I'd offer her the opportunity if she'd like to add any thoughts on that.

17 COMMISSIONER BARAN: Please, yeah.

18 DR. BIER: Yeah, I do think it's worth, as Joy said, relooking
19 at the safety goals now in light of new reactor designs, so we do have a small,
20 kind of informal working group going forward. Former Commissioner
21 Apostolakis is going to speak to us about this in August, August 24th, I believe.

22 And I think it's too soon to say whether we are going to have any concrete
23 recommendations out of that process.

24 But I think when you look at both smaller reactor sizes,

1 inherently safe designs, and the fact that the rest of the world has gotten safer
2 also, we're not necessarily competing against coal plants anymore as the
3 alternative energy source. I do think it's worth just taking another look at it, and
4 maybe a year, or two from now I'll have more to say about that concretely.
5 Thank you.

6 DR. REMPE: And just for clarity I note that the briefing
7 interaction with Former Commissioner Apostolakis will be held as an open
8 subcommittee meeting under the Policy and Procedures Subcommittee. So, the
9 working group discusses it, but we have these presentations, they are posted,
10 and meet all the FACA guidelines.

11 DR. BIER: Yes, thank you.

12 COMMISSIONER BARAN: Thanks, very interesting. Let me
13 -- there are so many different questions I could ask, so many different topics to
14 cover. Maybe I'll ask one of the big questions is this idea whether we need two
15 frameworks in the rule, or could have just one that would cover everything.
16 Dave, I got the sense from you, you were pretty skeptical given the
17 philosophical differences between the two frameworks, that it was practical
18 really to pull them together.

19 I'm interested in any thoughts you, or others have about, I
20 guess both the desirability of having one framework, rather than two, and then
21 the practicality of combining them, or I guess desirability, or practicality of a
22 more guidance approach, someone suggested that, don't try to combine them,
23 put those two frameworks in guidance, and have just higher level performance
24 criteria in the rule. Any thoughts about that?

1 DR. PETTI: In terms of one, or two, I think of it as you come
2 to the fork in the road, and you have to decide to go left, or right. They both get
3 you to the destination, but they're two separate highways. So, practically I don't
4 know there's a big difference. If you combine them, it's like being on a road,
5 and you've got to get off of this -- if you want to do more risk based, you've got
6 to get off at this exit.

7 But you stay on, and you get off, and there's like 15 different
8 exits that you're going to have to get on, and off of. So, it's difficult. I think
9 there's a greater chance to mess up, because you'll have to say well, if you're
10 going to do this, if it's this approach, this is what you're doing, if it's not, then it's
11 that approach, so I think practically it's a concern.

12 This idea of moving the framework stuff into guidance, my
13 view is it's kind of like what the Brits do, because the Brits have a very high
14 level sort of thing. They have a handful of reactors. Our existing regulatory
15 fabric, to put framework A, and B, what are the safety functions, what are the
16 design criteria down in guidance, you've created a huge difference from 50 and
17 52 in my opinion.

18 Never mind just the enforceability, it's a different level of
19 safety, because then they can say no, we don't want to do that, we're going to
20 do this. And that will just extend, because that will just open up questions in my
21 mind. I'm not as worried about the two separate rules. Initially, we had many
22 discussions in the Committee about, why don't you combine them?

23 But if you go back and read the preamble, and understand the
24 foundations beneath it, you really see that they're really different. And although

1 at first brush they look similar, the rationale for them is different enough that
2 combining them is, as I said, it's like oil, and water. In a sense, it's just you
3 decide which highway you're on to get to the answer.

4 COMMISSIONER BARAN: Thanks, very helpful.

5 CHAIR HANSON: Thank you, Commissioner Baran.
6 Commissioner Wright.

7 COMMISSIONER WRIGHT: Thank you, Chair. And thank
8 you very much for your presentations, there's a lot that's floating around out
9 here, and I don't know that we can assuredly cover it in the two hours that we
10 have, but I want to appreciate what you do, your willingness to serve, and to do
11 this. It's a very difficult job at times, and I thank you for what you do.

12 Joy, I'm going to start with you, you're the leader, so we're
13 coming to you. You spoke a little bit about the NIA report a second ago, we
14 also had the INL report that was out there too, that was one of the ones you
15 kind of referenced without naming it. And I heard your comments when
16 Commissioner Baran was talking to you.

17 Can you give me your thoughts, and I understand your
18 position where you're coming from, but if we understand what the industry is
19 saying, and what these trade groups are saying as well, these NGOs, the first
20 of a kinds are coming, right? And the intent is for them to be standardized, the
21 intent, because they're trying to meet national security goals, global security
22 goals, carbon goals, you pick one.

23 But when you get down to it, they're looking at potentially
24 streamlining this, okay? So it's your first of a kind, maybe up to two, or three, or

1 four before you get to your Nth of a kind cost, and stuff like that, and if they are
2 truly cookie cutter designs, to simplify it. What are your thoughts on the
3 benefits of reviewing every application in that case, if we're on an Nth of a kind
4 review? Which is I think that's what the intent of what the comments are.

5 DR. REMPE: Again, I think ACRS doesn't want to waste time
6 on looking at issues we've already looked at. But on the other hand, if it's put
7 in, for example, if the Atomic Energy Act were to change, one might say well, do
8 we really need to do a standard design approval if you've already done a
9 reactor, or you've got a certified design? Well, is it really the same, or did you --
10 we've had changes where they're significant power upgrades.

11 Is that really the same? So, I guess that was one thing, you
12 need to be careful how that language is changed.

13 COMMISSIONER WRIGHT: So, I understand, because we're
14 all stuck, the agency is still stuck in that one off big plant design, they're all
15 different, and I understand that. But in this situation, what we're hearing, and I
16 have no reason to dispute it, because you keep hearing every CEO, every
17 CNO, every designer talking about it, that this is going to be our design.

18 If you want to do something different, we're not selling it to
19 you. This is how it's going to be. Once we get a design certified by the NRC,
20 that's what we're going to sell, that's what we're going to go to market with.
21 Now, maybe down the road they may change it, and again, I'm all for it, but if
22 we're really talking that way --

23 DR. REMPE: If we're really talking that way, then you start
24 looking at site hazards, and co-located hazards, and things like that. But I think

1 that ACRS --

2 COMMISSIONER WRIGHT: Exactly, which is not really
3 novel, right?

4 DR. REMPE: The staff would be able to deal with it. But
5 again, I'm thinking of what's coming down, and if changes were made, what if
6 you have a certified design, but you say I haven't built it yet, and I'd like to
7 tweak it, well how big is that tweak?

8 COMMISSIONER WRIGHT: Well, that's a change --

9 DR. REMPE: Yeah, again, that's how you change it.

10 COMMISSIONER WRIGHT: But that's not what we're
11 hearing, okay? And that's what we have to pay attention to, I understand that,
12 right?

13 DR. REMPE: Yeah, but then again, I'm from Missouri, and I
14 guess I look at what I see written down in front of me in the near term, and so I
15 would be careful, and make sure that the -- how one focuses that scope is done
16 very carefully so that one doesn't miss some things.

17 COMMISSIONER WRIGHT: I mean I understand, we've
18 heard -- not to pick on him at all, but we've heard Jeff Lash over at TVA talking
19 about hey, I'm coming not with one, but my intent is to come with 12, or 20, and
20 we're going to do them all the same to start with, and once we get some of it
21 done, the fast followers are coming, right? And they're going to be the same
22 way.

23 So, I understand, so I think we as an agency have to be open
24 to get into more of a production kind of mind set, rather than a one off review on

1 everything.

2 DR. KIRCHNER: I think, Commissioner Wright, I think it
3 would be a very expedited review. If indeed they achieve the Nth of a kind, and
4 there weren't substantial, or significant changes in the design, such as a major
5 power upgrade, or something. We are seeing that, I think we mentioned in your
6 presentation, we touched on SLA, subsequent license renewal applications.

7 The first two, or three that we looked at, we took a lot more
8 time, but our colleague Matt Sunseri, who was former chair, took a much more
9 expeditious, or expedited approach to how we would do those reviews. So, we
10 learn from the application of the GALL reports for SLR, and we know what to
11 look for on the subsequent applications. Because it's not a one to one match
12 for your example.

13 But it's an example of how I think both the agency has
14 expedited their reviews, and focused on the key aging issues, and we've done
15 the same. So that typically it's one meeting for that particular review.
16 Theoretically, if we get to the Nth of a kind, that would be great for the industry,
17 and for the agency. I think our review would be just perfunctory almost.

18 COMMISSIONER WRIGHT: Well, quite honestly for the
19 world.

20 DR. KIRCHNER: But as Joy pointed out, the other big issue
21 would be the siting.

22 COMMISSIONER WRIGHT: Right, and I understand that.

23 DR. PETTI: I mean we touched on it earlier, if the engineers
24 are doing their job right, they're engineering out all the internal initiator risk, and

1 your risk sits with the external, and that's kind of a different setup, right? So,
2 when you go to site selection, that's why the seismic stuff is so important. If you
3 can get a seismic isolator, then you decouple yourself from the site a little bit.
4 Then you don't have significant site adaptations, and things like that.

5 That's where the answer is going to be, and I don't think we've
6 ever kind of been in that situation, where we've got to worry about -- the
7 external stuff is what's really important. But I agree with Walt, if it's truly Nth of
8 a kind, yeah.

9 DR. REMPE: I'd also note that when we had this international
10 exchange, we have seen other examples, in France for example, where that
11 type of situation, and there's a class. So, there's international experience for
12 this too.

13 COMMISSIONER WRIGHT: Yeah, but I do think that the way
14 things are being presented today, it is a paradigm shift because of the global
15 security nature of this. And if we don't get it right here in the U.S., they're not
16 going to be able to sell anything across the pond, because it takes that here.
17 I've heard that more, and more recently, and I believe it's true. So, I'm going to
18 go a little bit further with you in the couple minutes I got.

19 So, you mentioned earlier that you're continuing to streamline
20 your reviews, right? And I like that, I think it's awesome. Okay. Anything we
21 can do to make things more efficient, I'm all for it, as long as we're hitting that
22 safety strike zone. So, let's talk a little bit about the meetings too. So, I mean
23 you can speak, and I appreciate you speaking on how you're really looking at
24 streamlining your processes.

1 But how are you addressing outside concerns as well, that
2 technical questions during the meetings can veer past the point of addressing
3 safety significance, and more into the area of technical curiosity. Can you? Are
4 y'all getting a handle on that too?

5 DR. REMPE: I believe in recent years you'll see that
6 sometimes other members will tell a member hey, we already discussed that.
7 So, we are cognizant of that. I would also though, in fairness to those kind of
8 comments, would note that our process sometimes is a probe to understand if
9 something has been addressed. I think the issue about the combustible gas
10 generation might have surprised some of the applicants when we first brought it
11 up a bit.

12 And although they said they were starting to develop models
13 for it, there was no indicator that that had been considered in the application.
14 And so, again, it may come as a bit of a surprise, and sometimes we bring it
15 back, and explain why we're interested in that issue, but I think sometimes our
16 questions may be perceived as off target. And if the member can't justify it,
17 then we will move on, and it's not just intellectual curiosity we hope.

18 COMMISSIONER WRIGHT: Okay, thank you. And I'm going
19 to come back to you real quick with the 30 seconds I've got. So, you mentioned
20 your visit to SHINE last year, and I recognize the value of seeing the facility in
21 person, it always makes an impression, it helps, right? But I'm really interested
22 in hearing a little bit more about how those interactions at the site helped you
23 better inform your decisions, and gave you better insights, can you get a little bit
24 more specific about what you --

1 DR. BALLINGER: Yeah, that's a very simple answer, yes.

2 COMMISSIONER WRIGHT: How, in what way?

3 DR. BALLINGER: When you talk to the people at the site,
4 you get -- you're standing around, and you're getting to ask questions which you
5 would not see, you wouldn't even think of if you're reading a chapter.

6 COMMISSIONER WRIGHT: Like what? Give me an
7 example.

8 DR. BALLINGER: Like characteristics of the site, shielding,
9 interaction with the public, the airport that's within walking distance of the thing.
10 And also the design itself, and the safety issues related to design, the hot cell
11 setup, all this kind of stuff. And you get to ask questions, especially they
12 provided what I would call the overall construction manager, as well as the
13 technical person.

14 And those folks answered every question that you could ask.
15 And so, as a result of that, when it came back to assembling the chapter letters,
16 and putting the overall letter together, that had a big effect on how we
17 constructed the letter. We may say well, going in we should discuss this. We
18 went out there, and we talked to them about this topic, and we now understand
19 it a lot better, and we don't need to put that in the letter. So, I can't emphasize
20 that more.

21 COMMISSIONER WRIGHT: That's what I was trying to drill
22 down to to get some specifics, so thank you for that, I appreciate it. Thank you,
23 Chair.

24 CHAIR HANSON: Thank you, Commissioner Wright. And

1 we'll finish up here today with Commissioner Caputo.

2 COMMISSIONER CAPUTO: Good morning. I'm glad to be
3 part of this meeting today, but I'd like to start by welcoming Dr. Vicki Bier. Dr.
4 Bier, I'm sorry I'm not there to say hello to you in person, go Badgers. I didn't
5 actually have a class from Dr. Bier, but I remember her well from my time at
6 UW, and I'm thrilled to see you participating on the ACRS. Dr. Petti, thank you
7 for briefing us on the Kairos Hermes test reactor review, and how it built on the
8 lessons from NuScale, and SHINE reviews.

9 I understand that the committee held ten meetings over the
10 course of three years for a review of seven topical reports for both the non-
11 power, and power reactor applications of Kairos' technology. For the non-
12 power test reactor construction permit, the Committee held four multiple day
13 meetings at the subcommittee level, and one meeting at the full Committee over
14 this three year time span.

15 Was the Committee able to gain any efficiencies from the
16 extensive pre-application interactions on the topical reports?

17 DR. PETTI: Yes, thank you, very good question. Absolutely.
18 When everything came together for the full Committee, we had the answers
19 already from the topical report. So, we really like the pre-engagement, and the
20 early topicals. It kind of just aligns everything in your mind, so that when you
21 see the application, you understand yeah, okay, now I remember that there.

22 So, it's the same thing as the chapters, you can't just review
23 one chapter in absentia of another chapter, they're so interactive. So, that's this
24 whole sequencing thing that really has a lot of efficiency gains, but you've got to

1 think it all through, and that's a huge lesson learned, and we're going to use it
2 going forward.

3 COMMISSIONER CAPUTO: Okay. In the future, when the
4 Committee is reviewing a Kairos power reactor application, do you expect the
5 Committee's level of effort to increase, and include additional meetings?

6 DR. PETTI: Hard to say at this point. Certainly the
7 documentation itself will be larger in volume, and there will be more detail. If it's
8 only at the CP stage, maybe not. That may be more sort of an OL question,
9 because at the CP, you've got a lot more flexibility. So, at the power reactor
10 stage, it may be, particularly if they take all the lessons they learned from
11 Hermes, and apply it, I think the CP could be faster, assuming they're going to
12 go Part 50.

13 COMMISSIONER CAPUTO: All right, and going forward, do
14 you anticipate the Committee's level of effort to be similar for other advanced
15 reactor technologies we varying degrees of pre-application engagement?

16 DR. PETTI: Yes, but again, depending on the technology,
17 and what they bring, and the level of detail that they bring. Almost all of them
18 that we've talked to are doing a Part 50 two step. A lot of them are well along
19 on their technology development. From what we can tell, we know what the key
20 topical reports are that are in the system, Joy talked about, that we reviewed
21 with NRR staff.

22 Looks like the top five that she had on her slide, they have the
23 right topical reports, everyone is kind of following everybody else, and that's
24 good, I think that's going to help streamline things. And I honestly think the way

1 we think about the letter, and how we probe, and think about it is also going to
2 help that.

3 COMMISSIONER CAPUTO: So, given the level of effort that
4 you've had on Kairos, and anticipate going on the future, and I understand what
5 Chairman Rempe discussed in terms of cautioning against new, and novel
6 reviews, but isn't it going to be awfully difficult for the ACRS to not only review
7 initial designs, or initial licensing on these technologies, but also to review a
8 consistent work load, hopefully, of these designs going forward?

9 Which gets back to Commissioner Wright's discussion about
10 shouldn't get this to be fairly routine, and wouldn't it be the wisest use of the
11 Committee's time to be doing new, and novel, or initial reviews of technologies,
12 rather than each, and every subsequent license?

13 DR. PETTI: Again, depending on if they're truly talking about
14 a standardized design, and they have an SDA, and nothing has varied, then
15 you're left with just evaluating the site differences. That should be possible at
16 Nth of a kind.

17 COMMISSIONER CAPUTO: Okay. I appreciated the
18 discussion so far on the Part 53 review, and Commissioner Baran's question on
19 quantitative health objectives. I'd also like to make a few observations on it,
20 since the proposed rule is certainly at the forefront of the Commission's focus
21 right now. As Dr. Petti pointed out, the staff's proposed framework A builds on
22 the licensing modernization project that the Commission approved for use as
23 guidance in 2020.

24 And that guidance, Reg Guide 1.232, is one of the valuable

1 pieces of Part 53 that's currently being used by applicants under the present
2 Part 50 and 52. There's a lot to like in Part 53 with regard to proposing a
3 framework that the licensing modernization framework project fits more neatly
4 into than it does within a more deterministic framework like 50, or 52.

5 There's a lot in Part 53 that builds on prior work of the
6 Commission and the staff that is currently found in policy statements and
7 regulatory guidance. But I believe the Committee and the Commission should
8 think long and hard whenever it's considering whether methods that have
9 historically been acceptable in guidance should be codified in regulations.

10 Codifying those methods may sounds simple, but may create
11 significant complications, not the least of which is how to manage needed
12 modifications that may arise in the future. There will also be lost flexibility, and
13 lost opportunity for developing innovative methods that may differ from that
14 approach. Similarly, codifying policy statements should not be taken lightly.

15 We can assume that there were very good reasons why prior
16 commissions chose to address these issues as policy statements at the time.
17 Codification of safety goals is a prime example of this. In February, the ACRS
18 Subcommittee on Regulatory Policies and Practices was briefed on the
19 quantitative safety goals. The briefing noted that they were not considered to
20 be absolute or viewed in isolation, and that there may be excellent reasons to
21 allow operation above a goal.

22 That thought has been a consistent Commission policy since
23 adoption of the safety goals. The practical ramification of codifying the safety
24 goals would be to set a more stringent standard for advanced reactors than we

1 have for the currently operating fleet, contrary to the repeated Commission
2 direction in both SRM-10-0121, and again more recently in SRM-19-0117.

3 As I understand it, the ACRS reviewed, and made
4 recommendations to the Commission at the time that were consistent with what
5 was issued, particularly with regard to the QHOs not being intended to be
6 absolute requirements enshrined in regulation. Our reliability principle of good
7 regulation states once established, regulations should be perceived to be
8 reliable, and not unjustifiably in a state of transition.

9 So, reflecting on the response to Commissioner Baran's
10 question, what is a compelling justification for the Committee to depart from this
11 longstanding agency opposition as opposed to using, or directing effort toward
12 other surrogates? Dr. Petti?

13 DR. PETTI: So, as I understood it, surrogates were allowed
14 in the guidance that's there, that they can be innovative, and come up with
15 different ones. We had raised, in one of our letters, concern about the
16 applicability of the existing surrogates because they don't fit well. But this may
17 be a case where there's differing guidance in the agency.

18 Because there's numerous reg guides and SECYs that talk
19 about the qualitative health objectives being used; it's in NEI 18-04, it's in the
20 non-PRA standard, and the like. And that may be reflected, there may be a
21 time component here, right? When it was initially developed, now you look
22 back on it and reflect on where you are today, and how helpful it's been with the
23 current fleet, and then try to project to the future.

24 COMMISSIONER CAPUTO: But the examples that you

1 mentioned, aren't those enshrined in guidance, not rulemaking text?

2 DR. PETTI: Yes, they're in guidance, in the SECY, which is
3 policy, I'm not --

4 COMMISSIONER CAPUTO: Right. So, the justification for
5 putting them into rule text is a lack of identifying something else.

6 DR. PETTI: No, I think one of the other issues, which we
7 haven't touched about is, I think a public perception issue. That it could be
8 seen as the NRC moving away from those goals which are important.

9 COMMISSIONER CAPUTO: Well, if they are currently in
10 guidance, and would stay in guidance, that doesn't sound like much of a
11 justification for shifting them into rule text, they're not going away.

12 DR. PETTI: Well, but you wouldn't have to, if they're in
13 guidance, you wouldn't have to meet them. And I would -- I don't know why
14 we'd want an advanced reactor that was less safe than the existing fleet in
15 terms of where they sit relative to the QHOs.

16 COMMISSIONER CAPUTO: But the implementation of the
17 QHOs in rule text for advanced reactors sets a far more stringent safety level,
18 and that's --

19 DR. PETTI: I disagree. I think these advanced reactors, if
20 they're designed well, will have ample margin to the goals. None of them that
21 we have seen I think will be so close. There should be significant margin when
22 the numbers are done.

23 DR. REMPE: And the tabletops reflect that.

24 DR. PETTI: And the tabletops I think reflect that.

1 COMMISSIONER CAPUTO: So, is that really a justification
2 for shifting away from a longstanding agency position, though?

3 DR. PETTI: The argument for putting it in the rule has more
4 to do with having a metric to assure an equivalent level of safety to what's there
5 in 50 and 52. That, without it, there's a hole, and the staff might feel compelled
6 to put in additional requirements that could be -- well, that, A, could be more
7 difficult to make a technology neutral as such.

8 COMMISSIONER CAPUTO: But, part of the discussion
9 earlier, wouldn't it be simpler to use something like the PAGs rather than the
10 QHOs? Because as I mentioned in my remarks, there are ample justifications
11 for operating beyond the QHOs.

12 DR. PETTI: I think the staff wanted to give flexibility to
13 developers. Because the PAGs are a more restrictive set of requirements, it's
14 basically one to five REM at your site EPZ, which is usually the site boundary,
15 that's much more restrictive than the QHOs, but if they meet them, then it gives
16 you some assurance you can meet the QHOs.

17 COMMISSIONER CAPUTO: Well, I definitely don't think I
18 agree with you on whether the QHOs are less restrictive, or more restrictive. I
19 believe them to be far more restrictive. I also believe them to be incredibly
20 complicated when it comes to compliance space, and having to meet those on
21 a day by day basis, and the nature of how to prove that.

22 DR. PETTI: I would say that the current fleet meets the
23 QHOs with good margin, but cannot meet the EPA PAGs at their site boundary,
24 which is why they have emergency planning. So, the advanced reactors should

1 be able to meet the PAGs, then implicitly meet the QHOs.

2 COMMISSIONER CAPUTO: So, then what purpose do the
3 QHOs serve if they need to meet the PAGs? If they can meet the PAGs, and
4 don't need anything more restrictive?

5 DR. PETTI: It's flexibility. Somebody may decide they don't
6 want to meet the PAGs at their site boundary for some reason.

7 COMMISSIONER CAPUTO: All right, well I think you, and I
8 certainly will have to agree to disagree on whether meeting the QHOs is
9 actually possible, and attractive. One last question, Dr. Ballinger, you
10 discussed the Committee's visit to the SHINE facility under construction in
11 Wisconsin, and the Committee's consideration of the staff, training, caliber, and
12 commitment.

13 That sounds more appropriate to an oversight role fulfilled by
14 NRC staff in licensing, and operation space. Isn't that kind of pushing the
15 boundaries of the Committee's role?

16 DR. BALLINGER: No. I think that we were in the process of
17 reviewing the application, and so anything that we can do to advance, and help
18 that review, I think is perfectly appropriate. Now, it turned out that that visit was
19 very instructive, and very useful in our review. I think it actually made it easier
20 to do the review.

21 And so, I think that that visit, and such visits that achieve that
22 goal are the right thing to do. There may be cases where a visit to a plant, or
23 some site just simply doesn't add value to the review process, but in this case, I
24 personally believe, and I think that our other members would agree that the visit

1 did add very significant value, and probably shortened the review process.

2 COMMISSIONER CAPUTO: Well, I don't doubt that the visit
3 was very helpful. It's just the observation about evaluating staff during the visit
4 gave me pause.

5 DR. REMPE: If I could help? I would like to --

6 DR. BALLINGER: Are you talking about the staff that was
7 with us?

8 COMMISSIONER CAPUTO: No, you had a bullet that there
9 were -- that during the visit the Committee evaluated the licensee's staff, and
10 made observations about their training, caliber, and commitment.

11 DR. BALLINGER: I'm not sure we were doing evaluations of
12 the facility staff. I would say that getting to know them, and their demonstrated
13 degree of knowledge of their plant, and their construction was very helpful. But
14 we weren't evaluating the staff. We were just -- I'm just acknowledging the fact
15 that they were very competent, and we observed that.

16 DR. REMPE: If I could supplement Member Ballinger's
17 response, one of the items I started to bring up when Commissioner Wright
18 queried him about the visit was we actually saw a mock up where the staff was
19 -- the SHINE staff would be training on how they would conduct some of their
20 actions, and as you may recall in the letter, we did mention how the human
21 actions, we had some questions about the repetitiveness, and that was very
22 helpful at least for me to see during that visit.

23 COMMISSIONER CAPUTO: Okay, thank you, I don't have
24 any other questions. Thank you, Chairman.

1 CHAIR HANSON: Thank you, Commissioner Caputo. We
2 have reached the end of our time together, thank you all very, very much.
3 Thanks to my colleagues for your insightful comments, and questions, and
4 thanks to the members of the ACRS, and thank you for your service to the
5 agency, and to the country, we really appreciate it very much, and thank you for
6 the good discussion today. With that, we're adjourned.

7 (Whereupon, the above-entitled matter went off the record at
8 11:53 a.m.)